Nurix Therapeutics, Inc. (NRIX) Investor Relations Documents

Nurix Therapeutics, Inc. (NRIX) investor relations documents from the company's IR site: 8 presentations, 10 press releases; latest deck 2026-05-14. Read in-app with summaries. First-party data.

BTK degradation by bexobrutideg suppresses B cell activation and FcεRI-mediated degranulation in preclinical models of chronic spontaneous urticaria: Bexobrutideg, a catalytic BTK degrader, demonstrates superior potency in suppressing B cell activation and mast cell degranulation in preclinical CSU models.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-04Press releaseNurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in
2026-08-04Press releaseNurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
2026-07-21Press releaseNurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potenti
2026-07-09Press releaseNurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-06-11Press releaseNurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in
2026-06-08Press releaseNurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class
2026-05-14Press releaseNurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic
2026-05-14PresentationBTK degradation by bexobrutideg suppresses B cell activation and FcεRI-mediated degranulation in preclinical models of chronic spontaneous urticaria
2026-05-13Press releaseNurix Therapeutics to Participate in Upcoming Investor Conferences
2026-05-12Press releaseNurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
2026-04-22Press releaseNurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR
2026-04-22PresentationDiscovery and Characterization of CBL-B Intramolecular Glue Inhibitors That Increase T Cell Activation and Suppress Tumor Growth
2026-04-21PresentationNRX-0305: an Orally Bioavailable, CNS Penetrant, Pan-Mutant BRAF Degrader Demonstrates Robust Efficacy in Intracranial Models of Melanoma Brain Metastasis and Primary Glioma
2026-03-24PresentationCombinatorial Optimization of Degrader-Antibody Conjugates Enabled by Automation
2025-12-12PresentationBexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in Patients with Waldenström Macroglobulinemia: Updated Results from an Ongoing Phase 1a/b Study
2025-12-08PresentationBexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial
2025-12-07PresentationMolecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation
2025-11-07PresentationNX-1607: Translational Insights From a First-in-Human Study of an Oral CBL-B Inhibitor in Advanced Solid Tumors

NRIX overview · NRIX earnings · NRIX financials · NRIX KPIs · NRIX documents · NRIX ownership · NRIX peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.